| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4260a256b5f28ea7d92b4c1f5b921d0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24043 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 |
| filingDate |
2014-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b55f94e815aae83cd92d3bddfaa8fc8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e854ee036eecf347b5d6efb38a6ee74 |
| publicationDate |
2016-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016108431-A1 |
| titleOfInvention |
Prevention and treatment of atrial fibrillation |
| abstract |
There is provided a nucleic acid that inhibits miR-31 in an atrial myocyte, for use in the prevention or treatment of atrial fibrillation in a subject. Also provided is a method for diagnosing or predicting the risk of atrial fibrillation in a subject, said method comprising: (i) determining the amount of miR-31 in a sample from the subject; (ii) comparing the amount of miR-31 in the sample with a reference standard; and (iii) identifying a difference in the amount of miR-31 in the sample relative to the reference standard; wherein an increase in the amount of miR-31 in the sample compared to the reference standard correlates with the presence of or an increased risk of atrial fibrillation in the subject; and wherein a decrease, or no difference in the amount of miR-31 in the sample compared to the reference standard correlates with the absence of an increased risk of atrial fibrillation in the subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021395747-A1 |
| priorityDate |
2013-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |